1. Home
  2. TVTX vs PAY Comparison

TVTX vs PAY Comparison

Compare TVTX & PAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

SELL

Current Price

$48.93

Market Cap

4.7B

Sector

Health Care

ML Signal

SELL

Logo Paymentus Holdings Inc.

PAY

Paymentus Holdings Inc.

SELL

Current Price

$33.31

Market Cap

4.6B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
TVTX
PAY
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.6B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
TVTX
PAY
Price
$48.93
$33.31
Analyst Decision
Strong Buy
Buy
Analyst Count
15
7
Target Price
★ $75.14
$41.00
AVG Volume (30 Days)
★ 2.3M
794.2K
Earning Date
11-02-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 92.89
48.57
EPS
N/A
★ 0.57
Revenue
N/A
★ $1,196,507,000.00
Revenue This Year
$55.24
$22.95
Revenue Next Year
$43.78
$16.29
P/E Ratio
★ N/A
$58.75
Revenue Growth
N/A
★ 37.25
52 Week Low
$22.59
$20.11
52 Week High
$68.73
$45.31

Technical Indicators

Market Signals
Indicator
TVTX
PAY
Relative Strength Index (RSI) 47.24 52.88
Support Level $49.46 $29.61
Resistance Level $59.93 $37.91
Average True Range (ATR) 2.67 1.59
MACD 0.37 0.17
Stochastic Oscillator 76.14 64.74

Price Performance

Historical Comparison
TVTX
PAY

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About PAY Paymentus Holdings Inc.

Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: